Andelyn Biosciences Launches Dedicated Foundation to Deepen Rare-Disease Engagement

New updates have been reported about Andelyn Biosciences.

Andelyn Biosciences Inc. has established The Andelyn Foundation as a standalone 501(c)(3) nonprofit to formalize the company’s long-term commitment to rare and ultra-rare disease communities and strengthen its strategic positioning as a patient-centric cell and gene therapy CDMO. The initiative complements Andelyn’s core viral vector manufacturing business by funding patient-founded organizations, expanding advocacy relationships, and reinforcing the company’s brand with sponsors and investigators that prioritize community engagement alongside scientific execution.

The foundation will focus on directing proceeds each year to a single patient-led group for targeted financial support, spanning research-related needs, clinical trial readiness, travel, and urgent care expenses, while simultaneously running storytelling and outreach programs to raise awareness of rare conditions. Its primary fundraising engine is the annual Fore One Purpose Golf Tournament in Ohio, which has already distributed $100,000 to beneficiary organizations and will hold its third event on August 24, 2026, offering Andelyn a recurring, visible platform to engage partners, clients, and local stakeholders around its rare-disease mission.